

The CPE Brief

September 2026

Tailored Insights for You



Expert Consensus Guides Severe Alopecia Areata Treatment

A US expert panel reached consensus on treatment approaches for adults with severe alopecia areata, identifying oral JAK inhibitors as the primary, long-term therapy. The article also outlines alternative and supplemental treatment options.

[Read the Consensus Statement](#)

EVO756 Fails to Meet Phase 2b Endpoint in Atopic Dermatitis

Evimmune reported that EVO756 did not meet the primary or secondary endpoints in a Phase 2b trial of adults with moderate-to-severe atopic dermatitis. The company will discontinue development of EVO756 in AD while advancing EVO301 in AD.

[More Details](#)

YCANTH Completes Phase 3 Enrollment for Common Warts

Verrica Pharmaceuticals completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts, with topline results expected in early 2027. The second Phase 3 trial has surpassed 50% enrollment.

[Read More](#)

Repegaldesleukin Shows Positive Phase 2b Results in Atopic Dermatitis

Phase 2b results showed reppegaldesleukin significantly improved disease severity, skin clearance, and itch compared with placebo in adults with moderate-to-severe atopic dermatitis. The findings support continued evaluation in the ongoing Phase 3 ZENITH AD program.

[Learn More](#)

AbbVie Completes Acquisition of Apogee Therapeutics

AbbVie completed its acquisition of Apogee Therapeutics, adding zumilokibart, an IL-13 inhibitor in late-stage development for atopic dermatitis, to its immunology pipeline. The acquisition also includes additional programs targeting inflammatory and immunologic diseases.

[Read the Press Release](#)

Across the pipeline, dermatology continues to advance treatment options in atopic dermatitis and alopecia areata, alongside progress in common warts and broader immunology development.

CPE Spotlight

A New CPE Offering!


Case-Based Product Theater

What if your next product theater felt more like a clinical discussion than a presentation?

Our Case-Based Product Theater offering brings:

- Realistic patient scenarios that put clinical data into context
- Interactive discussion that engages HCPs in treatment decisions
- A practical approach that connects evidence to everyday patient care

Patient-First Approach



Explore Our Website

Our new website offers a closer look at how CPE connects science, strategy, and education to support meaningful healthcare engagement.

[Visit us at cpeducate.com](#)

Below is a list of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

Medical Affairs

Asynchronous Engagements
KOL Identification & Contracting
MOA Visualization
MSL Training
Patient Education
Poster Presentations
Scientific Platform Development

Medical Affairs Marketing

Advisory Boards
(Virtual or In-Person)
Conference Planning
Content Development
Core Slide Decks
KOL Engagements
Publications

Marketing

Branding & Visual Aids
Healthcare Event Production Management
Launch Preparation
Product Theater Planning & Logistics
Speaker Bureau Services
Speaker Training
Technical Productions

CPE's **Case-Based Product Theater** offering brings evidence to life through realistic patient scenarios, while our **At the Table™** and **Dedicated KOL Brand Ambassador** programs create new opportunities for meaningful HCP and KOL engagement.

Ready to bring your next program to life? Reply to this email and let's talk.

With appreciation,

Allison Goldberg, MPA
Associate Vice President
CPE Communications
Cell: 917-509-9583
agoldberg@cpeducate.com

When you're ready to explore how the CPE Communications Team can support your company, contact Allison at agoldberg@cpeducate.com

